Anhui Anke Biotechnology

Anke Biopharmaceutical (stock code: 300009.SZ) develops, produces, sells, and services biopharmaceuticals as a high-tech enterprise listed on China’s Growth Enterprise Market.

Anhui Anke Biotechnology Group Co’s shares decline by 2.49% in trading on October 27, 2026, closing at **7.82 CNY** after falling from a prior close of **8.02 CNY**. The company operates in the biotechnology sector within the China market. The drop reflects short-term trading volatility without additional context on underlying drivers.

Oct 2026Global Banking & Finance ReviewNews article

Anhui Anke Biotechnology receives NMPA approval for a clinical trial application of its CD7-targeted CAR-T therapy, **PA3-17**, expanding its use to pediatric and adolescent patients. The therapy, developed in-house, targets cancer treatment with a novel CAR-T approach. This marks a key regulatory milestone for the company’s expanding pipeline in China.

Dec 2025Insight, China's Pharmaceutical IndustryNews article

Anhui Anke Biotechnology secures NMPA approval to advance clinical trials for **AK2017**, a recombinant human growth hormone Fc fusion protein injection. The company, listed on the Shenzhen Stock Exchange (SHE: 300009), now proceeds with human testing for the therapeutic candidate. AK2017 targets potential growth-related medical applications under regulatory oversight.

Dec 2022Insight, China's Pharmaceutical IndustryNews article

Anhui Anke Biotechnology acquires a 30% stake in Hubei 377 Biological Technology from Yang Ming. The transaction finalizes a strategic investment in the biotech sector, expanding Anhui Anke’s portfolio in biological research and development. The deal marks a significant step in Anhui Anke’s growth through minority equity participation.

Oct 2017MarketScreenerNews article